10x Genomics, Inc. Class A Common Stock (TXG) — 分析摘要
10x Genomics, Inc. Class A Common Stock（TXG）的市值为9.80十亿美元，最近一年的营收同比增长了+5.2%。净利润率为-6.8%。当前市盈率为-130.4倍。
核心要点
- 营收同比变化+5.2%
- 净利润率-6.8%
- 市盈率-130.4倍
与LABORATORY ANALYTICAL INSTRUMENTS板块的其他公司相比，TXG的营收增长为+5.2%，市盈率为-130.4倍。
10x Genomics, Inc. Class A Common Stock (TXG)
前收盘价 2026-10-12 · 市场数据 POLYGON · 财务数据 SEC EDGAR
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -29461.3x — 盈利不足以覆盖利息支出
营业利润率为 -14.3% — 经营亏损显著
净利润较上一期下降 72.5%。
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
行业
LABORATORY ANALYTICAL INSTRUMENTS
员工人数
1,178
总部
PLEASANTON, CA
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。